Is there a connection btween selling pressure and soon to be announced merger?

The decline in NLS Pharmaceutics' (NLSP) stock price and the subsequent selling pressure are not directly related to an imminent merger. The factors contributing to the stock's decline are primarily technical in nature:

1. **Technical Sell Signal**: The sell signal issued from a pivot top point on June 30, 2025, is a key factor contributing to the stock's decline. This signal suggests a bearish trend in the short term, leading to selling pressure.
2. **Weak Technical Forecast**: The recent downgrade of NLSP's stock to a Buy Candidate indicates that the stock may not perform well in the near term. This downgrade could have influenced the stock's price negatively, leading to further selling interest.
3. **Market Sentiment**: The mixed market sentiment on July 2, 2025, where the Dow Jones surged while the Nasdaq slid, could have contributed to the selling pressure. This sentiment does not directly relate to the upcoming merger but rather reflects broader market dynamics.

While it is possible that investors may be anticipating the outcome of the merger and adjusting their positions accordingly, the primary driver of the selling pressure is technical in nature. The upcoming merger is not the direct cause of the recent decline and selling pressure.